Auwaerter on Infectious Diseases

Paul G. Auwaerter, MD, MBA, has disclosed no relevant financial relationships. Dr. Auwaerter is a paid consultant to Medscape, and his participation and contributions do not constitute endorsement by The Johns Hopkins University, Hospital, or Health System.
- Why I Don't Worry About Nephrotoxicity With Zosyn
2
- New Federal Oversight of Lab Developed Tests
1
- Late Summer Fevers: History Is Paramount
- New and Emerging Options for Treating Recurrent C difficile
1
- From ECCMID: New Anti-Viral and Bacterial Drugs of Interest
- COVID-19 Rebound: Is Treatment Worth It?
8
- Hit Pandemic Show Is Fantastical but Not Baseless
2
- Measles in the United States: Should We Worry?
5
- IDWeek 2022 IDWeek 2022: COVID News for Clinical Practice or FDA Consideration
- Should I Be Immunized, and When? A COVID-19 Booster Update
2
- Monkeypox and HIV: Same but Different?
2
- COVID-19: Updates and Predictions for the Bivalent Booster
2
- Monkeypox Outbreak: Monitoring, Diagnosis, and Treatment
- Paxlovid Rebound: What Is Happening?
2
- A Surprising Cause of Abdominal Pain and Other GI Symptoms
9
- Is the Epstein-Barr Virus Associated With COVID-19?
11
- Treatment Considerations for Pregnant Women With COVID-19
- A Quick Tour of the New Lyme Disease Guideline
7
- COVID-19: Updated Mask Guidance From the CDC
3
- Monoclonals for COVID-19 a 'Minor Contribution'
5